Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Reality Check

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Aug 09, 2023 1:33pm

216 Views

Post# 35579916

RE:RE:RE:Reality Check

This is very difficult to handicap. Win or lose it is amost a certainty to be in the text books.

I still think GOBLET and Roche are the key. mBC is difficult and complex, and ONC/Y has not brought any clarity for me. So I wonder if Roche has learned enough from AWARE-1, BRACELET, and AN's Phase 3 mBC Bridging Study to move on both mBC and PDAC which is apparently what ONCY wants.

Further, if Roche is contemplating a move, do they really want PanCAN. Nothing against PanCAN just a question. Roche is the key to the PDAC trial not to mention CRC.

I have no opinion on the share price. I am holding what I have at this moment; perhaps not as gleefully as a month ago.

Cheers

<< Previous

Bullboard Posts

Next >>

Online behaviour puts Canadians at risk of cyberattacks, study finds